April 7, 2021
The PharmaHemp Story
PharmaHemp started to build an Active Pharmaceutical Ingredients (API) production plant in accordance with current European Union Good Manufacturing Practices (EU GMP), which will enable the company to expand into the medical cannabis market.
PharmaHemp is at the forefront of innovative solutions in the rapidly expanding cannabis-related industry. The company produces a wide variety of hemp-infused products with the lowest THC level possible in Europe. Such products include oils, concentrates, cosmetics, and other hemp-derived products.
PharmaHemp’s key competitive advantage on the market is the provision of complete solutions in the field of Phyto cannabinoids and commitment to continuous innovation, quality, transparency and full traceability of their materials and processes.
The company offers innovative development services, stability studies and customized formulations as well as certified supply, processing and distribution of Phyto-cannabinoid-based raw materials. All analyses are done in their accredited in-house laboratory.
Each step in PharmaHemp’s production cycle or analytical task is closely monitored and documented in order to ensure full traceability of materials and processes involved. In other words, the company’s team performs diligent quality control and quantitatively determines cannabinoid levels.
PharmaHemp offers a broad variety of products with the lowest possible THC level in Europe, which are produced to the highest quality standards within certified GMP production capacities.
Their dedication to quality is validated by independent and external supervisory bodies. PharmaHemp is certified with the GMP standard for Good Manufacturing Practice for food and cosmetics and is accredited under the ISO/IEC 17025, the highest standard for testing and calibration laboratories. This accreditation proves that the company operates with the highest competency level in terms of laboratory testing of hemp and hemp-related products for growers, producers and end users. Its accredited test reports are accepted globally without the need for further testing, which in turn improves international trade.
PharmaHemp also successfully passed an FDA audit in 2020, which further proves their products are safe and meet all regulatory requirements to export to the USA. Moreover, its business operations are in compliance with the following quality systems; GACP, GDP, GLP, GMP, ISO 9001 and certified under ISO 22000, ISO 22716 and ISO/IEC 17025.
Last, but not least, PharmaHemp commenced their new production facility initiative, including a new Active Pharmaceutical Ingredients (API) plant. The new facility is projected to be built by the end of 2022 and will combine all production, laboratory, R&D, warehouse and corporate efforts. PharmaHemp believes their expansion is an important chapter in their story and a vital step in their mission to continue to improve lives drop by drop.
We are proud to be one of the few producers in EU that have an inhouse cannabinoid profiling laboratory accredited under ISO/IEC 17025.
Andrej Sušnik, CEO of PharmaHemp
The European Cannabis Report: 6th Edition takes a deep dive on the current social, economic, regulatory and health trends. The report also includes sales forecasts of medical and adult-use cannabis in the US and Canada.
The PharmaHemp Story
Catch up on our newest articles that you might have missed